GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (FRA:2UV) » Definitions » Short Percentage of Float

Applied Therapeutics (FRA:2UV) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Applied Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Applied Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's Short Percentage of Float falls into.


;
;

Applied Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (FRA:2UV) » Definitions » Short Percentage of Float
Comparable Companies
SKYE DTIL PDSB CTMX VICP IKNA CYCC VTVT SER QNCX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
APLT:USA 2UV:Germany
Address
545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017
Website
https://www.appliedtherapeutics.com
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Applied Therapeutics Headlines

No Headlines